Following a recent story with the top twenty companies in the area of AI drug development, this time we will make a flight over this new ecosystem looking for the bright lights of a rigorous developing market.
In a recent article about new drugs approved, we found out that in the record year 2018, 61 new drugs were launched which means 20% more new pharmaceutical products compared with the previous record year 1996. It is no wonder if AI drug development realises the promises, that we will witness an explosive growth in the coming years. Some of the 20 most prominent companies have some very fresh news that it is worth our attention.
As of 30 June, Frontier IP Group Plc (LON:FIPP) have a 5% holding in Exscienta
Frontier IP (LON:FIPP) unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group’s work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.